Carol Suh is a Partner with ARCH Venture Partners. She joined ARCH in 2018 as an Associate and was named Partner in 2021. Ms. Suh focuses on identifying and evaluating new life science technologies and is involved in company creation. Ms. Suh is a co-founder of Neumora Therapeutics (NMRA), currently serving as its Chief Operating Officer. She is a co-founder of Orbital Therapeutics and serves on its Board of Directors. She also serves on the Board of Directors of HI-Bio.
Prior to ARCH, Ms. Suh helped launch Magenta Therapeutics, and she also was a consultant at Trinity Partners, working with a wide range of biotech and pharma companies on corporate strategy, market research, and business development. Ms. Suh began her career in R&D Strategy with GlaxoSmithKline’s Regenerative Medicine group. For her work, she was recognized on the 2015 Forbes 30 Under 30 list in Healthcare. Ms. Suh is a stem cell biologist by training and combines her scientific expertise with experiences on the business side of biotech.
Ms. Suh holds an A.B. in Molecular and Cellular Biology from Harvard University, where she trained under Dr. David Scadden at the Harvard Stem Cell Institute. She holds an M.Phil from Yale University, where she was awarded the National Science Foundation Graduate Research Fellowship for her work in stem cell biology. She completed her M.B.A. at the Stanford Graduate School of Business.